We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BD DIAGNOSTIC SYSTEMS

BD Diagnostics manufactures and markets medical supplies and devices and diagnostic systems that include cellular ana... read more Featured Products: More products

Download Mobile App




Bacterial Panel Detects Stool Pathogens from Swabs

By LabMedica International staff writers
Posted on 25 Apr 2017
Repeated bouts of diarrhea and persistent diarrheal disease disrupt intestinal function and absorption, making diarrheal disease a leading cause of malnutrition in children less than 5 years of age. Importantly, diarrheal disease is both treatable when correctly diagnosed and preventable via proper infection control measures.

In the USA, Salmonella, Campylobacter, Shigella, and Shiga toxin-producing Escherichia coli are the most common bacterial pathogens, and they are usually associated with foodborne illnesses. Identifying the cause of diarrhea is important for the treatment of patients and for public health intervention through outbreak management.

Microbiologists at Cincinnati Children’s Hospital Medical Center collected 272 sequential rectal swab samples from August 2015 to December 2015 for conventional bacterial culture and Shiga Toxin testing, as standard of care. The team evaluated a molecular test to detect pathogens from the stool swabs. Discrepant test results were resolved using Verigene Enteric Pathogens Nucleic Acid Test (EP) on the Verigene System.

The molecular test evaluated was the BD MAX Enteric Bacterial Panel (BDM-EBP), which is designed and FDA-cleared to detect Salmonella, Shigella, Campylobacter, and Shiga toxin genes stx1/2 from stool samples. There were also 36 challenge samples (13 Salmonella spp., three Shigella spp., 10 Campylobacter spp., and 10 Shiga toxin positive Escherichia coli) that were tested using reference strains and previous patient isolates diluted to103-104 cfu/mL in saline then added to Sample Buffer Tube (SBT) with negative stool matrix delivered via a swab.

The scientists found that from a total of 272 rectal swab specimens that were evaluated, 89 were positive by culture and/or MAX EBP. All discrepant results were BDM-EBP positive and culture negative. There were 21/31 (68%) of the apparent false positive BDM-EBP discrepant results resolved as positive with Nanosphere’s Verigene EP. They reported that 8.8% of the patient samples did not initially yield a result on the BDM-System. Upon repeat, half of the problematic samples resolved, and 4.4% of the total specimen tested did not yield a result. All organisms in the challenge samples were detected.

The authors concluded that although stool is the optimal specimen for identifying enteric bacterial pathogens, polymerase chain reaction (PCR) from swabs is more sensitive than culture from swabs, and rectal swabs can be used for testing with BDM-EBP for detection of Salmonella spp., Shigella spp., Campylobacter spp., and Shiga toxin 1 and 2 genes. Additionally, BDM –EBP PCR results are available 34 to 47 hours sooner that with conventional cultures from rectal swabs. The study was published on April 8, 2017, in the journal BMC Clinical Pathology.


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Immunofluorescence Analyzer
MPQuanti
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.